AB Science announces a slight delay in the publication of its 2025 half-year financial report
30/09/2025 – The Company will publish its financial report for the first half of 2025 on Friday 10 October, 2025, at the latest
AB Science announces the successful completion of a 2.55 million euros private placement
04/08/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors
AB Science receives regulatory approval from european countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025 – AB Science today announced the approval of the third of four stages of the Phase I/II study with the compound AB8939 in adult patients with relapsed/refractory acute myeloid leukemia
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS
24/07/2025 – AB Science today announced that the confirmatory Phase 3 study with masitinib in amyotrophic lateral sclerosis has been authorized by the first set of European countries
AB Science announces the successful completion of a EUR 1.925 million private placement
08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefit
04/07/2025 – AB Science today announced that a confirmatory phase 3 trial of masitinib in metastatic castrate resistant prostate cancer has been authorized by FDA and EMA, with a biomarker that targets patients with less advanced metastatic disease
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors
30/06/2025 – AB Science today announced that an agreement in principle has been reached with its financial creditors to postpone by 24 months the repayment of its bank debt
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
23/06/2025 – AB Science today announced that a new study from an independent research team based in China presents new evidences showing that masitinib offers a promising new approach to treating Alzheimer’s disease
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
12/06/2025 – AB Science today announced that the patent office of Canada has granted a patent protecting the composition of matter of AB8939, and closely related compounds, until 2036
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
09/06/2025 – AB Science today announced that the European Medicine Agency (EMA) has approved the extension of the shelf life of its veterinary medicine MASIVET® from 36 months to 48 months